Skip to main content
Z

Zhejiang Jolly Pharmaceutical Co.,LTD — Investor Relations & Filings

Ticker · 300181 ISIN · CNE100001096 LEI · 300300OKJYAXUOICFE42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,793 across all filing types
Latest filing 2026-05-20 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300181

About Zhejiang Jolly Pharmaceutical Co.,LTD

https://www.zuoli.com、www.jolly.com.cn

Zhejiang Jolly Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of pharmaceutical products, with a primary focus on medicinal fungi and modern traditional Chinese medicine. The company utilizes advanced fermentation technology to produce its flagship product, the Wuling Capsule, which is widely used for treating insomnia, anxiety, and depression. Its product portfolio also includes Bailing tablets and other formulations derived from high-quality medicinal fungi. The firm emphasizes the integration of traditional medicinal knowledge with modern biotechnological processes to ensure product efficacy and safety. By maintaining a robust supply chain and focusing on specialized therapeutic areas such as mental health and respiratory support, the company serves a broad clinical market. Its operations encompass the entire value chain from raw material cultivation and fermentation to final product manufacturing and marketing.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 84% confidence The document is a corporate announcement detailing the 2025 annual equity distribution implementation, specifying cash dividend per share, total dividend amount, ex‐dividend and record dates, dividend payment methods, adjustments for repurchased shares, and related schedules. This is not an earnings release, not an annual or interim report, and instead matches a Notice of Dividend Amount.
2026-05-20 Chinese
关于向不特定对象发行可转换公司债券的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 85% confidence The document is an announcement about the company’s application and updates relating to the issuance of convertible corporate bonds to unspecified investors, including responses to the exchange’s review inquiries and revisions to the prospectus and issuance plan. This clearly concerns the company’s financing activities (convertible bond issuance). It is not the final issuance but an ongoing update on the financing process. Therefore, it fits the Capital/Financing Update category (CAP).
2026-05-20 Chinese
国金证券股份有限公司关于浙江佐力药业股份有限公司向不特定对象发行可转换公司债券之发行保荐书（修订稿）
Capital/Financing Update Classification · 87% confidence The document is an underwriter’s/sponsor’s formal opinion letter (“发行保荐书”) supporting Zhejiang Jolly Pharmaceutical’s convertible bond issuance to unspecified investors. It provides detailed due diligence, legal and financial analyses, and a recommendation to proceed with the bond financing. This clearly pertains to a company’s capital raising and financing activity (convertible debt issuance), matching the definition of a Capital/Financing Update (CAP).
2026-05-20 Chinese
上海东方华银律师事务所关于浙江佐力药业股份有限公司申请向不特定对象发行可转换公司债券之补充法律意见书（二）（修订稿）
Capital/Financing Update Classification · 80% confidence The document is a detailed legal opinion from Shanghai Dongfang Huayin Law Firm regarding Zhejiang Zuoli Pharmaceutical’s proposed issuance of convertible corporate bonds to unspecified investors, including substantive legal due diligence on authorizations, issuer qualifications, substantive conditions for issuance under Company Law, Securities Law, and related rules. It is clearly part of the company’s financing activity and capital structure change, not an earnings release, board announcement, or mere report publication notice. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-20 Chinese
浙江佐力药业股份有限公司向不特定对象发行可转换公司债券募集说明书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed “募集说明书” (prospectus) for Zhejiang Jolly Pharmaceutical’s offering of convertible corporate bonds to unspecified investors. It contains sections on issuance background, terms, risk factors, financial information, bond structure, and use of proceeds. This is not an annual or interim report, but a financing document describing a capital raising via convertible bonds. According to the definitions, this aligns with a Capital/Financing Update (CAP).
2026-05-20 Chinese
关于浙江佐力药业股份有限公司申请向不特定对象发行可转换公司债券的审核问询函之回复（修订稿）
Regulatory Filings Classification · 85% confidence The document is a detailed response by Zhejiang Zoli Pharmaceutical and its sponsor to a review inquiry letter issued by the Shenzhen Stock Exchange regarding the company’s application to issue convertible bonds to unspecified investors. It is not the bond prospectus itself, nor a financial report or earnings announcement, but a regulatory compliance filing addressing exchange queries. This falls into the general “Regulatory Filings” category as a compliance document.
2026-05-20 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.